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Introduction. HIV produces a chronic, progressive and irreversible infection, altering the host 
defense mechanisms, installing AIDS and opportunistic infections, with invariable progression to 
death, in absence of treatment. HIV infection rapidly affects young and fertile people, who are 
receptive to injectable drugs use, and practicing unprotected sexual intercourse that favors the 
spread of the epidemic. AIDS is a global epidemic with about 40 million infected people. 
Twenty million people have died since the early 1980s because of AIDS-related complications. 
Every ten seconds, in the world, a person dies of AIDS. According to WHO, the most common 
cause of women's mortality worldwide is AIDS. 50% of newly infected people are aged between 
15 and 25 years. At the end of 2016, 11.043 HIV-infected were registered in Moldova, and 
during the first nine months of 2017, 614 patients were newly diagnosed. The estimated number 
of all bearers is about 15 thousand citizens of Moldova. 
Case report. Patient M., 31 years, driver, was hospitalized with the diagnosis of HIV and many 
coinfections: chronic viral hepatitis B, toxic hepatitis, ascites, chronic pancreatitis, and chronic 
cholecystitis. Clinical picture: general weakness, periodic pronounced pain in the right side of 
abdomen, loss of appetite, nausea, and asthenia.  Period of hospitalization: 27 days. The 
diagnosis was confirmed in 2009, the route of infection was sexual, but the patient also used 
injectable drugs. During the hospitalization he received antiretroviral treatment: Darunavir 600 
mg once a day, Ritonavir 600 mg twice a day, Tenofovir + Lamivudine 1x1, and symptomatic: 
Mezym, Verospiron, Panangin, Furosemide, Hepasol, Sorbilact, Infusol, Hemodez, Lipesol, 
Arginine. The patient was discharged with the recommendation to be under the supervision of 
the infectious disease doctor, and to continue the antiretroviral and symptomatic treatment, 
repeated control over 3 months. 
Conclusions. HIV / AIDS is a chronic, lifelong disease without known healing, and infected 
people have to be medically monitored for the rest of their lives. Antiretroviral therapy aims to 
prolong lifetime duration and improve the quality of life of patients.  
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Introduction. The fixed dose combined pharmaceutical medicine represent an association of 
two or more drug substances, using in several branches, including the hypopotassemia treatment 
(potassium concentration in the blood plasma is below 3.5 mmol/l). For example: Panangin, 
Asparcam, Antikircel. The single-component therapy with potassium chloride, potassium iodide 
or other potassium salts ensures the essential pharmaco-therapeutic in up to 50% of the medical 
treatment cases, therefore it is less effective, than using of combined pharmaceutical medicine, 
that shows better results in hypopotassemia. In particular, those combinations of pharmaceutical 
substances are plausible which achieve not only the removal of the hypopotassemia symptoms 
(cramps, cardiac arrhythmias), but also the causal treatment. 
Aim of the study. Evaluation of the combined pharmaceutical products market used in 
hypopotassemia in the Republic of Moldova (RM). 
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Materials and methods. The analysis of the pharmaceutical market of RM, the study of the 
State Nomenclature of Medicines. 
Results. As a result of the detailed analysis of the pharmaceutical market in the RM it was 
determined that the basic producters of the combined medicines, using in the treatment of 
hypopotassemia, are Romania - 42%, Ukraine - 21%, Russia - 17%, Germany - 9%, US - 6 %, 
Hungary - 5%. Unfortunately, the monocomponent potasium medicines predominate (70%) on 
the pharmaceutical market of the RM, which provides only a daily dose of this electrolyte. There 
is not any native combined medicine in RM. Basing on this fact, it is proposed to elaborate a new 
combined pharmaceutical product containing potassium aspartate, magnesium aspartate, 
potassium orotate and spironolactone, which will be able to ensure adequate causal treatment in 
hypopotassemia due to stopping of the potassium losses (renal or extrarenal) and regulation of 
metabolic disorders, which generates the normalization of potassium potential in cells. 
Conclusions. The actuality and usefulness have demonstrated the necessary of the research 
initiating to elaborate the native combined pharmaceutical product, which would be accessible, 
effective, convenient and low in toxicity 
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Introduction. Propolis is known as one of natural products with multiple therapeutic effects, 
such as: antimicrobial, antibiotic, anti-inflammatory, analgesic, antioxidant, antifungal and anti-
tumor. This apiculture product has a very complex composition, consisting of the following 
groups of active principles: phenols, flavonoids, amino acids, volatile oils, steroids, minerals, etc. 
The development of pharmaceutical forms with propolis extract is a very actual problem. 
Aim of the study. Technology development and standardization of suppositories with soft 
propolis extract. 
Materials and methods. Analysis of State Nomenclature of drugs of the Republic of Moldova. 
Use of hand rolling and molding methods and different excipients to prepare suppositories with 
propolis extract. 
Results. The analysis of State Nomenclature of drugs of the Republic of Moldova denotes a very 
low content of preparations with soft extract of propolis. Most of the suppositories have anti-
inflammatory action (25%); followed by analgesic-antipyretic (15%); immunomodulators (14%), 
etc.  
Suppositories with soft propolis extract were formulated in the compounding department of 
Vasile Procopisin Pharmaceutical University Center. The excipients used were cocoa butter, 
PEG 4000:400 (9:1) and PEG 4000:1500:400 (6:3:1). The performed quality tests on 
appearance, melting rate, dissolution rate and uniformity of mass met the quality standards 
required by European Pharmacopoeia. 
Conclusions. The technology of preparation of suppositories with soft propolis extract by two 
methods, using different excipients was elaborated and quality assessment was performed. 
The results of the research will allow the introduction of suppositories with soft propolis extract 
in assortment of Vasile Procopisin Pharmaceutical University Center as elaborations. 
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